New Study On Prevention Of Transfer Of HIV

New Study On Prevention Of Transfer Of HIV.
An antiviral sedative may serve protect injection drug users from HIV infection, a late study finds. The study of more than 2400 injection drug users recruited at 17 painkiller treatment clinics in Thailand found that daily tablets of tenofovir reduced the risk of HIV infection by nearly 49 percent, compared to unmoving placebo pills infection. One expert said an intervention to support shield injection drug users from HIV - the virus that causes AIDS - is much needed.

And "This is an noted study that opens up an additional option for preventing HIV in a hard-to-reach population," said Dr Joseph McGowan, medical principal at the Center for AIDS Research and Treatment at North Shore University Hospital in Manhasset, NY. He celebrated that "HIV infections at to occur at high rates, with over 2,5 million worldwide and 50000 remodelled infections in the US each year bahan herbal. This is despite widespread knowledge about HIV infection and the motion it is spread, through unprotected sex and sharing needles for injecting drugs".

The participants included in the untrained study were followed for an average of four years. During that time, 17 of the more than 1200 patients taking tenofovir became infected with HIV, compared with 33 of an balanced number of patients taking a placebo, according to the learn published online June 12, 2013 in The Lancet. Further analyses of the results showed that the shielding effect of tenofovir was highest among those who most closely followed the drug's prescribed regimen.

In this group, the peril of HIV infection was reduced by more than 70 percent, said study leaders Dr Kachit Choopanya and Dr Michael Martin, superintendent of clinical research for the Thailand Ministry of Public Health-US Centers for Disease Control and Prevention Collaboration. Prior experiment with has shown that anticipatory use of antiviral drugs cuts the risk of sexual transmission of HIV in both heterosexual couples and men who have going to bed with men, and also reduces mother-to-child transmission of HIV.

But this is the first study to show that this closer might also be effective among injection drug users. Worldwide, injection drug use is believed to cause one in 10 inexperienced HIV infections. But rates of infection associated with injection drug use are far higher in some areas of the world, such as eastern Europe and inner Asia.

In these regions, up to 80 percent of brand-new HIV infections are caused by injection drug use. According to McGowan, tenofovir is no "silver bullet" that would, on its own, assassinate the risk of HIV infection for drug abusers. But it could be a description ingredient in reducing the odds.

So "Adoption of this strategy, not as a stand-alone, but in conjunction with needle exchange, counseling, opiate substitution, communal support and mental health therapy may enable us to get to the fore of this expanding epidemic". He added that the participants in the study were also provided with what's known as "directly observed therapy," where the upper is administered under the observance of a health care worker.

Services like this, along with monthly HIV testing and condom distribution, might not appear in "real life" treatment situations so outcomes might not be as considerable as in this clinical trial. Another expert agreed that adherence to tenofovir treatment is key to success herbalms.com. Tenofovir "accumulates slowly in the body, making the case for adherence - which is strongly associated with the efficacy of the drug," said Victoria Richards, helper professor of medical sciences at the Frank H Netter MD School of Medicine at Quinnipiac University, in Hamden, Conn.